AI assistant
Tyra Biosciences, Inc. — Director's Dealing 2024
Sep 21, 2024
32575_dirs_2024-09-20_fdda7d4e-e236-4a4c-9239-2c03e3c0adcb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Tyra Biosciences, Inc. (TYRA)
CIK: 0001863127
Period of Report: 2024-09-18
Reporting Person: Harris Todd (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-09-18 | Common Stock | S | 3500 | $24 | Disposed | 1502427 | Direct |
| 2024-09-19 | Common Stock | S | 5671 | $24.3014 | Disposed | 1496756 | Direct |
| 2024-09-19 | Common Stock | S | 27 | $25.0969 | Disposed | 1496729 | Direct |
| 2024-09-20 | Common Stock | S | 7109 | $24.1877 | Disposed | 1489620 | Direct |
Footnotes
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022.
F2: Represents the weighted average sale price for the entire number of shares sold within a one dollar price range. The actual sale prices range between $24.00 to $24.9749. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $24.00 to $24.8963. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.